ABL111 Combination Therapy Enters Global Phase 2...Evaluating First-Line Treatment for Metastatic Gastric Cancer
Co-developed by ABL Bio and Novabridge
Simultaneous Targeting of Claudin 18.2 and 4-1BB
ABL Bio announced on February 17 (local time) that it has begun dosing the first patient in a global Phase 2 clinical trial of the combination therapy of ABL111 (Givastomig), which is being co-developed with its U.S. partner Novabridge Biosciences.
This Phase 2 trial is designed to evaluate the potential of the combination therapy of ABL111, the programmed cell death protein 1 (PD-1) inhibitor nivolumab, and the chemotherapy regimen mFOLFOX6 as a first-line treatment for patients with metastatic gastric cancer. The two companies plan to assess approximately 180 patients who are positive for Claudin 18.2 and PD-L1.
ABL111 is a bispecific antibody that simultaneously targets Claudin 18.2 and 4-1BB, and is one of the pipelines developed on the 4-1BB-based bispecific antibody platform Grabody-T. Claudin 18.2 is a protein expressed in gastric mucosal epithelial cells that becomes overexpressed on the cell surface when cancer develops and is utilized as an anticancer target. 4-1BB is a receptor expressed on the surface of immune cells such as T cells, and when activated, it amplifies antitumor immune responses.
In a prior Phase 1b trial, the objective response rate (ORR) of the ABL111 combination therapy at 8 mg/kg was 77%, and the ORR at 12 mg/kg was 73% (19/26). ABL Bio explained, "Consistent responses were observed regardless of the patients' PD-L1 and Claudin 18.2 expression levels," adding, "The safety profile was also similar to that of the current first-line standard of care, demonstrating overall favorable tolerability."
Lee Sanghoon, CEO of ABL Bio, said, "Since ABL111 demonstrated best-in-class potential in the Phase 1b trial, we expect to see strong results in this Phase 2 study as well."
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
Philippe Denis, Chief Medical Officer (CMO) of Novabridge, said, "This study was designed to validate data in a broader patient population, ranging from PD-L1-positive patients to Claudin 18.2-positive patients," adding, "We expect to announce the top-line results of the Phase 2 trial in 2027, and the Phase 1b data are scheduled to be released in the second half of this year."
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.